Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Heidelberg Pharma AG    WL6   DE000A11QVV0

HEIDELBERG PHARMA AG (WL6)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Heidelberg Pharma AG : Notification and public disclosure of transactions by persons

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 04:40pm CEST


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

10.11.2017 / 16:34
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Name and legal form: NewMarket Venture Verwaltungs GmbH

2. Reason for the notification

a) Position / status
Person closely associated with:
Title: Prof. Dr.
First name: Christof
Last name(s): Hettich
Position: Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Heidelberg Pharma AG

b) LEI
391200E09XYBYITR1W32 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Derivative
ISIN: DE000A2GSZC6

b) Nature of the transaction
Granting of 40,141 subscription rights on zero coupon convertible bonds

c) Price(s) and volume(s)
Price(s) Volume(s)
0 EUR 0 EUR

d) Aggregated information
Price Aggregated volume
0 EUR 0.0000 EUR

e) Date of the transaction
2017-11-09; UTC+1

f) Place of the transaction
Outside a trading venue



10.11.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Internet: www.heidelberg-pharma.com

 
End of News DGAP News Service

38789  10.11.2017 


© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HEIDELBERG PHARMA AG
10/11HEIDELBERG PHARMA AG : Partner Magenta Therapeutics Exercises Option To Further ..
EQ
10/11HEIDELBERG PHARMA AG : Interim management statement on the first nine months of ..
EQ
10/08HEIDELBERG PHARMA AG : quaterly sales release
09/28HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
09/13HEIDELBERG PHARMA AG : Release according to Article 41 of the WpHG [the German S..
EQ
09/13CORRECTION OF A RELEASE FROM 30.05.2 : 00 CET/CEST - Heidelberg Pharma AG: Relea..
EQ
09/13CORRECTION OF A RELEASE FROM 30.04.2 : 46 CET/CEST - Heidelberg Pharma AG: Relea..
EQ
08/23HEIDELBERG PHARMA AG : Partner Telix Pharmaceuticals Files Phase III Trial for K..
EQ
07/26HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
EQ
07/12HEIDELBERG PHARMA : reports on first half-year
EQ
More news
News from SeekingAlpha
2016Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target 
Financials (€)
Sales 2018 3,50 M
EBIT 2018 -11,8 M
Net income 2018 -12,0 M
Finance 2018 31,6 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 7,27x
EV / Sales 2019 8,23x
Capitalization 57,0 M
Chart HEIDELBERG PHARMA AG
Duration : Period :
Heidelberg Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HEIDELBERG PHARMA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,31 €
Spread / Average Target 86%
EPS Revisions
Managers
NameTitle
Jan Schmidt-Brand Chief Executive Officer & Chief Financial Officer
Christof Hettich Chairman-Supervisory Board
Andreas Pahl Head-Research & Development
Friedrich von Bohlen und Halbach Member-Supervisory Board
Georg F. Baur Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HEIDELBERG PHARMA AG-34.44%66
CELLTRION, INC.--.--%29 086
IQVIA HOLDINGS INC26.93%25 281
LONZA GROUP18.00%23 371
INCYTE CORPORATION-34.51%13 299
SEATTLE GENETICS, INC.36.58%11 555